SAN DIEGO and SAN FRANCISCO, December 22, 2014 — ViaCyte, Inc., a privately-held regenerative medicine company with the first stem cell-derived islet replacement therapy for the treatment of diabetes in clinical trials, today announced that Dr. Paul Laikind, President and Chief Executive Officer, will present and participate in moderated panel discussions at the upcoming Biotech Showcase™ taking place January 12-15, 2015 in San Francisco. The presentation details are as follows:
Session: State of the Regenerative Medicine and Advanced Therapies Briefing
Panel: “Dose, Delivery, Data: Understanding the Three D’s of Advanced Therapy Drug Development”
Date/Time: Monday, January 12th at 9:05 a.m. PST
Session: Company Presentation
Date/Time: Monday, January 12th at 11:30 a.m. PST
Session: JDRF-sponsored Workshop
Panel: “Type 1 Diabetes: Novel Therapies, Devices and Diagnostics on the Horizon”
Date/Time: Tuesday, January 13th at 8:00 a.m. PST
All of the presentations will take place at the Parc55 Wyndham San Francisco in Union Square. To register for the events or for more information, please visit Biotech Showcase’s website: http://www.ebdgroup.com/bts/program/index.php
Dr. Laikind will review recent progress with the company’s VC-01™ islet replacement product candidate for the treatment of type 1 diabetes, which recently entered the clinical phase of development. A Phase 1/2 trial to assess safety, tolerability, and efficacy of the product in human subjects with diabetes, called STEP ONE, or Safety, Tolerability, and Efficacy of VC-01 Combination Product in Type 1, was launched in September 2014, and the first implant was announced in October 2014.
ViaCyte is a privately-held regenerative medicine company focused on developing a novel cell therapy for the treatment of diabetes. ViaCyte is conducting a Phase 1/2 clinical trial of the Company’s lead product candidate VC-01 in patients with type 1 diabetes who have minimal to no insulin-producing beta cell function. ViaCyte’s VC-01 combination product is based on the production of pancreatic progenitor cells derived from human pluripotent stem cells. These progenitor cells are implanted in a durable and retrievable encapsulation device. Once implanted and matured, these cells are designed to secrete insulin and other regulatory factors in response to blood glucose levels. The VC-01 product is being developed as a potential long-term diabetes treatment without immune suppression, and without risk of hypoglycemia or other diabetes-related complications.
ViaCyte is headquartered in San Diego, California with additional operations in Athens, Georgia. The Company is funded in part by the California Institute for Regenerative Medicine (CIRM) and JDRF.
In-Site Communications, Inc.
T: (212) 452-2793